Back to search

Article

Susceptibility of Ceftazidime-avibactam in bloodstream infections caused by multidrug-resistant Enterobacterales and Pseudomonas aeruginosa

2026-01-22

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background and objectives</h4> Ceftazidime-Avibactam (CAZ-AVI) is one of the last options to treat Enterobacteriales and Pseudomonas aeruginosa carbapenem-resistant. We aim to describe the susceptibility profile of bloodstream isolates of Enterobacterales and Pseudomonas aerunosa to ceftazidime-avibactam (CAZ-AVI) among strains resistant to third- and fourth-generation cephalosporins and/...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9c9be601-f5c0-53bb-b992-c3d2c4cbae9e
DOI
10.64898/2026.01.20.26344478
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Susceptibility of Ceftazidime-avibactam in bloodstream infections caused by multidrug-resistant Enterobacterales and Pseudomonas aeruginosaDOI 10.64898/2026.01.20.26344478
Antimicrobial Susceptibility of Enterobacterales causing Bloodstream Infection in United States Medical Centres: Comparison of Aztreonam-Avibactam with Beta-Lactams Active against Carbapenem-Resistant EnterobacteralesSemantic proximity
Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019-2021): emergence of complex resistance phenotypes.Semantic proximity
Molecular characterization of clinically isolated Pseudomonas aeruginosa with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021Semantic proximity
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016-2018.Semantic proximity
Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative BacteriaSemantic proximity
Ceftazidime-avibactam resistance determination in carbapenem-resistant Klebsiella pneumoniae infections before its use in practiceSemantic proximity
Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infectionsSemantic proximity
Ceftazidime-Avibactam Use in a Cohort of Children with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development Following Difficult-to-Treat or Recurrent InfectionsSemantic proximity
Molecular Epidemiology of Infections Caused by Carbapenem-Resistant <em>Pseudomonas aeruginosa</em> and Enterobacterales and Susceptibility of Isolates to Ceftazidime-AvibactamSemantic proximity
Resistance to ceftazidime–avibactam and underlying mechanismsSemantic proximity
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR- P. aeruginosa )Semantic proximity
Ceftazidime-avibactam resistance in Klebsiella pneumoniae: A growing public health concern across diverse sublineages, 2019–2024Semantic proximity
Select a neighboring publication to make it the new centre.